MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN),

Shares of Ocugen, Inc. (NASDAQ: OCGN - Get Free Report) have earned a consensus rating of "Moderate

Ocugen NASDAQ: OCGN is positioning its ophthalmology gene therapy portfolio around treatments for in

OCGN posts a wider Q2 loss as R&D spending climbs, while advancing late-stage gene therapy programs

Ocugen NASDAQ: OCGN said its second quarter marked progress across its late-stage ophthalmology pipe

Ocugen, Inc. (OCGN) Q2 2026 Earnings Call Transcript

Ocugen (OCGN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate

Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.07) per share which missed the analyst consens

Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) c

MALVERN, Pa., July 31, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN),

RMAT designation is intended to help expedite development of new regenerative medicines that have po

MALVERN, Pa, July 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCG

MALVERN, Pa. , July 28, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN)

Cumulative sales milestones up to $255 million and modest upfront/near-term development milestonesRo

Cumulative sales milestones up to $255 million and modest upfront/near-term development milestones R

Ocugen NASDAQ: OCGN outlined plans to advance three late-stage retinal disease programs, with compan

MALVERN, Pa. , July 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN)

Ocugen (OCGN) reported earnings 30 days ago. What's next for the stock?

OCGN is advancing gene-agnostic eye therapies across retinal diseases, with key trial data and regul

Ocugen faces cash burn and dilution risks, but upcoming eye gene therapy data and planned filings th

Ocugen's three ocular gene therapy programs could deliver trial data, filings, and potential BLA mil

Canaccord Genuity analyst Whitney Ijem maintains Ocugen (NASDAQ:OCGN) with a Buy and lowers the p

Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.06) per share which missed the analyst consens

Dow futures up 100 pts. Shares of GeneDx Holdings (WGS) down 39.2% after cutting FY26 sales guidance

Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology l

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Ocugen (NASDAQ:OCGN) with a Buy

Ocugen stock falls after Phase 2 OCU410 data for dry AMD trails interim results, despite lesion redu

Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth

Canaccord Genuity analyst Whitney Ijem initiates coverage on Ocugen (NASDAQ:OCGN) with a Buy rati

Ocugen shares are surging Wednesday afternoon after Oppenheimer analyst Leland Gershell initiated co

Dow falls 200+ points as Serve Robotics Inc (NASDAQ: SERV) shares rise 16.2% on better-than-expected

Top Wall Street analysts changed outlook on top names. For all analyst rating changes, see analyst r

Oppenheimer analyst Leland Gershell initiates coverage on Ocugen (NASDAQ:OCGN) with a Outperform

Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.06) per share which met the analyst consensus

Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therap

Ocugen shares sank sharply Wednesday after the biotech company announces a $22.5 million underwritte

Ocugen Inc (NASDAQ:OCGN) shares are up on Friday as the company is gaining traction following positi

Ocugen reports early phase 2 data showing its eye gene therapy reduced lesion growth by up to 54%, w

OS Therapies releases trial data supporting FDA approval, U.K. and U.S. timelines, and potential eli

Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. cont

Study supports favorable safety and tolerability profile and clinically meaningful functional and st

Ocugen (NASDAQ:OCGN) reported quarterly sales of $1.752 million which beat the analyst consensus est